|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Demetri GD, van Oosterom AT, Garrett CR,
Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich
MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients
with advanced gastrointestinal stromal tumour after failure of
imatinib: A randomised controlled trial. Lancet. 368:1329–1338.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Blanke CD, Demetri GD, von Mehren M,
Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD,
Roberts PJ, Heinz D, et al: Long-term results from a randomized
phase II trial of standard-versus higher-dose imatinib mesylate for
patients with unresectable or metastatic gastrointestinal stromal
tumors expressing KIT. J Clin Oncol. 26:620–625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Demetri GD, Reichardt P, Kang YK, Blay JY,
Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M,
Joensuu H, et al: Efficacy and safety of regorafenib for advanced
gastrointestinal stromal tumours after failure of imatinib and
sunitinib (GRID): An international, multicentre, randomised,
placebo-controlled, phase 3 trial. Lancet. 381:295–302. 2013.
View Article : Google Scholar
|
|
5
|
McArthur GA, Demetri GD, van Oosterom A,
Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic
S and Fletcher JA: Molecular and clinical analysis of locally
advanced dermatofibrosarcoma protuberans treated with imatinib:
Imatinib Target Exploration Consortium Study B2225. J Clin Oncol.
23:866–873. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Butrynski JE, D'Adamo DR, Hornick JL, Dal
Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ,
Ramaiya N, et al: Crizotinib in ALK-rearranged inflammatory
myofibroblastic tumor. N Engl J Med. 363:1727–1733. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chibon F, Lagarde P, Salas S, Pérot G,
Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B,
et al: Validated prediction of clinical outcome in sarcomas and
multiple types of cancer on the basis of a gene expression
signature related to genome complexity. Nat Med. 16:781–787. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yen CC, Yeh CN, Cheng CT, Jung SM, Huang
SC, Chang TW, Jan YY, Tzeng CH, Chao TC, Chen YY, et al:
Integrating bioin-formatics and clinicopathological research of
gastrointestinal stromal tumors: Identification of aurora kinase A
as a poor risk marker. Ann Surg Oncol. 19:3491–3499. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yeh CN, Yen CC, Chen YY, Cheng CT, Huang
SC, Chang TW, Yao FY, Lin YC, Wen YS, Chiang KC, et al:
Identification of aurora kinase A as an unfavorable prognostic
factor and potential treatment target for metastatic
gastrointestinal stromal tumors. Oncotarget. 5:4071–4086. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hung GY, Yen CC, Horng JL, Liu CY, Chen
WM, Chen TH and Liu CL: Incidences of primary soft tissue sarcoma
diagnosed on extremities and trunk wall: A population-based study
in Taiwan. Medicine (Baltimore). 94:e16962015. View Article : Google Scholar
|
|
11
|
Liu CY, Yen CC, Chen WM, Chen TH, Chen PC,
Wu HT, Shiau CY, Wu YC, Liu CL and Tzeng CH: Soft tissue sarcoma of
extremities: The prognostic significance of adequate surgical
margins in primary operation and reoperation after recurrence. Ann
Surg Oncol. 17:2102–2111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Italiano A, Toulmonde M, Cioffi A, Penel
N, Isambert N, Bompas E, Duffaud F, Patrikidou A, Lortal B, Le
Cesne A, et al: Advanced well-differentiated/dedifferentiated
liposarcomas: Role of chemotherapy and survival. Ann Oncol.
23:1601–1607. 2012. View Article : Google Scholar
|
|
13
|
Singer S, Socci ND, Ambrosini G, Sambol E,
Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, et al:
Gene expression profiling of liposarcoma identifies distinct
biological types/subtypes and potential therapeutic targets in
well-differentiated and dedifferentiated liposarcoma. Cancer Res.
67:6626–6636. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dickson MA, Tap WD, Keohan ML, D'Angelo
SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy
MM, et al: Phase II trial of the CDK4 inhibitor PD0332991 in
patients with advanced CDK4-amplified well-differentiated or
dedifferen-tiated liposarcoma. J Clin Oncol. 31:2024–2028. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gobble RM, Qin LX, Brill ER, Angeles CV,
Ugras S, O'Connor RB, Moraco NH, Decarolis PL, Antonescu C and
Singer S: Expression profiling of liposarcoma yields a multigene
predictor of patient outcome and identifies genes that contribute
to liposarcomagenesis. Cancer Res. 71:2697–2705. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li C and Hung Wong W: Model-based analysis
of oligonucleotide arrays: Model validation, design issues and
standard error application. Genome Biol.
2:RESEARCH00322001.PubMed/NCBI
|
|
17
|
Li C and Wong WH: Model-based analysis of
oligonucleotide arrays: Expression index computation and outlier
detection. Proc Natl Acad Sci USA. 98:31–36. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstrale M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chou YS, Yen CC, Chen WM, Lin YC, Wen YS,
Ke WT, Wang JY, Liu CY, Yang MH, Chen TH and Liu CL: Cytotoxic
mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic
arrest, apoptosis, cellular senescence, and synergistic effect with
paclitaxel. Int J Oncol. 48:1187–1194. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmit TL, Nihal M, Ndiaye M, Setaluri V,
Spiegelman VS and Ahmad N: Numb regulates stability and
localization of the mitotic kinase PLK1 and is required for transit
through mitosis. Cancer Res. 72:3864–3872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu Y, Xu L, Zhang J, Hu X, Liu Y, Yin H,
Lv T, Zhang H, Liu L, An H, et al: Sunitinib induces cellular
senescence via p53/ Dec1 activation in renal cell carcinoma cells.
Cancer Sci. 104:1052–1061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Muller-Tidow C, Metzger R, Kügler K,
Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider
PM, Koeffler HP, Berdel WE and Serve H: Cyclin E is the only
cyclin-dependent kinase 2-associated cyclin that predicts
metastasis and survival in early stage non-small cell lung cancer.
Cancer Res. 61:647–653. 2001.PubMed/NCBI
|
|
26
|
Lens SM, Voest EE and Medema RH: Shared
and separate functions of polo-like kinases and aurora kinases in
cancer. Nat Rev Cancer. 10:825–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kelly KR, Ecsedy J, Medina E, Mahalingam
D, Padmanabhan S, Nawrocki ST, Giles FJ and Carew JS: The novel
Aurora A kinase inhibitor MLN8237 is active in resistant chronic
myeloid leukaemia and significantly increases the efficacy of
nilotinib. J Cell Mol Med. 15:2057–2070. 2011. View Article : Google Scholar
|
|
28
|
Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ,
Persky AM, Miller TP and Mahadevan D: Aurora inhibitor MLN8237 in
combination with docetaxel enhances apoptosis and anti-tumor
activity in mantle cell lymphoma. Biochem Pharmacol. 81:881–890.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kuilman T and Peeper DS:
Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev
Cancer. 9:81–94. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schoffski P, Chawla S, Maki RG, Italiano
A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, et
al: Eribulin versus dacarbazine in previously treated patients with
advanced liposarcoma or leiomyosarcoma: A randomised, open-label,
multicentre, phase 3 trial. Lancet. 387:1629–1637. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Demetri GD, Schöffski P, Grignani G, Blay
JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M
and Chawla S: Activity of eribulin in patients with advanced
lipo-sarcoma demonstrated in a subgroup analysis from a randomized
phase III study of Eribulin versus dacarbazine. J Clin Oncol.
35:3433–3439. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Demetri GD, von Mehren M, Jones RL,
Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K,
Tawbi H, et al: Efficacy and safety of trabectedin or dacarbazine
for metastatic liposarcoma or leiomyosarcoma after failure of
conventional chemotherapy: Results of a phase III randomized
multicenter clinical trial. J Clin Oncol. 34:786–793. 2016.
View Article : Google Scholar :
|
|
33
|
Chu CY, Chen CF, Rajendran RS, Shen CN,
Chen TH, Yen CC, Chuang CK, Lin DS and Hsiao CD: Overexpression of
Akt1 enhances adipogenesis and leads to lipoma formation in
zebrafish. PLoS One. 7:e364742012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fletcher CD, Akerman M, Dal Cin P, de
Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A,
Sciot R, et al: Correlation between clinicopathological features
and karyotype in lipomatous tumors. A report of 178 cases from the
chromosomes and morphology (CHAMP) Collaborative study group. Am J
Pathol. 148:623–630. 1996.PubMed/NCBI
|
|
35
|
Dei Tos AP, Doglioni C, Piccinin S, Sciot
R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher CD and
Tallini G: Coordinated expression and amplification of the MDM2,
CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol.
190:531–536. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lagarde P, Perot G, Kauffmann A, Brulard
C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R,
Schoffski P, et al: Mitotic checkpoints and chromosome instability
are strong predictors of clinical outcome in gastrointestinal
stromal tumors. Clin Cancer Res. 18:826–838. 2012. View Article : Google Scholar
|
|
37
|
Dickson MA, Mahoney MR, Tap WD, D'Angelo
SP, Keohan ML, Van Tine BA, Agulnik M, Horvath LE, Nair JS and
Schwartz GK: Phase II study of MLN8237 (Alisertib) in
advanced/metastatic sarcoma. Ann Oncol. 27:1855–1860. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huck JJ, Zhang M, McDonald A, Bowman D,
Hoar KM, Stringer B, Ecsedy J, Manfredi MG and Hyer ML: MLN8054, an
inhibitor of Aurora A kinase, induces senescence in human tumor
cells both in vitro and in vivo. Mol Cancer Res. 8:373–384. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Campisi J and d'Adda di Fagagna F:
Cellular senescence: When bad things happen to good cells. Nat Rev
Mol Cell Biol. 8:729–740. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dimri GP, Lee X, Basile G, Acosta M, Scott
G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O,
et al: A biomarker that identifies senescent human cells in culture
and in aging skin in vivo. Proc Natl Acad Sci USA. 92:9363–9367.
1995. View Article : Google Scholar : PubMed/NCBI
|
